Meng, Lingqi
Jin, Han
Yulug, Burak
Altay, Ozlem
Li, Xiangyu
Hanoglu, Lutfu
Cankaya, Seyda
Coskun, Ebru
Idil, Ezgi
Nogaylar, Rahim
Ozsimsek, Ahmet
Shoaie, Saeed
Turkez, Hasan
Nielsen, Jens
Zhang, Cheng
Borén, Jan
Uhlén, Mathias
Mardinoglu, Adil
Funding for this research was provided by:
Royal Institute of Technology
Article History
Received: 26 February 2024
Accepted: 22 September 2024
First Online: 2 October 2024
Declarations
:
: The protocol entailed the acquisition of written informed consent from all participants prior to commencing any procedures related to the trial. The trial adhered strictly to Good Clinical Practice guidelines as well as the principles outlined in the Declaration of Helsinki. The safety of participants and the risk-benefit analysis were supervised by an independent external data-monitoring committee. Approval for this study was granted by the ethics committee of Istanbul Medipol University, Istanbul, Turkey (Approval Date: January 22, 2020, Decision No: 7). This study is registered at with the Clinical Trial ID: NCT04044131; registration date: February 11, 2020.
: All participants provided their consent for publication of the study’s findings.
: A.M., J.B. and M.U. are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests.